Trial Information for Patients
Prostate cancer is one of the most common types of cancer found in men. That is one reason why READY is now enrolling participants for a clinical research trial aimed at evaluating treatment options for men with metastatic prostate cancer.
Many of today's standard treatments for cancer are based on earlier clinical trials. As a participant in a clinical research trial you could gain access to new investigational treatments before they are widely available.
About READY: A clinical trial for metastatic prostate cancer patients (CA180227)
You may be eligible for the READY trial if you have:
- Prostate cancer that has spread (metastasized) and progressed
- Undergone surgical castration or are currently undergoing hormone therapy
- No previous chemotherapy (except estramustine) to treat the spread of your cancer
The purpose of the READY trial (CA180227) is to assess whether the addition of dasatinib to docetaxel improves the overall survival of men with metastatic prostate cancer. All patients participating in this study will be treated with docetaxel, and half of all patients will also receive dasatinib.
Docetaxel is a chemotherapy that has been approved by many regulatory agencies, including the FDA, for the treatment of metastatic prostate cancer and is generally considered a standard treatment for this disease. Docetaxel, in monotherapy, is not considered an experimental treatment, as it may have been prescribed to treat your prostate cancer. Other medications normally given to patients taking docetaxel are prednisone and dexamethasone, which are also not considered experimental treatments.
Dasatinib is currently approved by many regulatory agencies, including the FDA, for patients who have chronic, accelerated, myeloid blast and lymphoid blast chronic myeloid leukemia (CML). It is currently being studied in adults who have solid tumor cancer(s), including metastatic prostate cancer, and is considered an "experimental treatment" for metastatic prostate cancer.
Talk to your doctor to learn more about the READY (CA180227) research trial.
To see if there is a Clinical Trial Site near you, click here.
To learn more about Prostate Cancer, click here.
To learn more about additional prostate cancer clinical trials, click on the link below.
NCT00861614 (lpilimumab)